<div><p>Although targeting of cancer cells using drug-delivering nanocarriers holds promise for improving therapeutic agent specificity, the strategy of maximizing ligand affinity for receptors overexpressed on cancer cells is suboptimal. To determine design principles that maximize nanocarrier specificity for cancer cells, we studied a generalized kinetics-based theoretical model of nanocarriers with one or more ligands that specifically bind these overexpressed receptors. We show that kinetics inherent to the system play an important role in determining specificity and can in fact be exploited to attain orders of magnitude improvement in specificity. In contrast to the current trend of therapeutic design, we show that these specificity in...
Introduction: Progressive breakthroughs in nanomedicine have been instrumental for the clinical tran...
The journey of chemotherapeutic drugs from the site of administration to the site of action is confr...
DDS promise to improve pharmacotherapy by optimizing: (i) drug solubility, (ii) its isola-tion from ...
Although targeting of cancer cells using drug-delivering nanocarriers holds promise for improving th...
Although the concept of selective delivery has been postulated over 100 years ago, no targeted nanom...
The recent advent of nanomedicine holds potential to revolutionize cancer therapy. This innovative d...
Cancer is one of the major global health problems, responsible for the second-highest number of deat...
The recent advent of nanomedicine holds potential to revolutionize cancer therapy. This innovative d...
Cancer is one of the leading causes of death worldwide. Regardless of advances in understanding the ...
Nanoparticles functionalized with multiple ligands can be programmed to bind biological targets depe...
Development of drug delivery systems (ie. nanocarriers) with controllable composition, architecture,...
&quot;Receptor-responsiveness&quot;, the change of receptors such as clustering after activa...
Since they were first reported in 1980, site-specific drug delivery nanocarriers have progressed gre...
Presently, nanocarriers (NCs) have gained huge attention for their structural ability, good biocompa...
Most of the conventional chemotherapeutic agents used against cancer have poor efficacy. An approach...
Introduction: Progressive breakthroughs in nanomedicine have been instrumental for the clinical tran...
The journey of chemotherapeutic drugs from the site of administration to the site of action is confr...
DDS promise to improve pharmacotherapy by optimizing: (i) drug solubility, (ii) its isola-tion from ...
Although targeting of cancer cells using drug-delivering nanocarriers holds promise for improving th...
Although the concept of selective delivery has been postulated over 100 years ago, no targeted nanom...
The recent advent of nanomedicine holds potential to revolutionize cancer therapy. This innovative d...
Cancer is one of the major global health problems, responsible for the second-highest number of deat...
The recent advent of nanomedicine holds potential to revolutionize cancer therapy. This innovative d...
Cancer is one of the leading causes of death worldwide. Regardless of advances in understanding the ...
Nanoparticles functionalized with multiple ligands can be programmed to bind biological targets depe...
Development of drug delivery systems (ie. nanocarriers) with controllable composition, architecture,...
&quot;Receptor-responsiveness&quot;, the change of receptors such as clustering after activa...
Since they were first reported in 1980, site-specific drug delivery nanocarriers have progressed gre...
Presently, nanocarriers (NCs) have gained huge attention for their structural ability, good biocompa...
Most of the conventional chemotherapeutic agents used against cancer have poor efficacy. An approach...
Introduction: Progressive breakthroughs in nanomedicine have been instrumental for the clinical tran...
The journey of chemotherapeutic drugs from the site of administration to the site of action is confr...
DDS promise to improve pharmacotherapy by optimizing: (i) drug solubility, (ii) its isola-tion from ...